CVAC Stock Overview
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.72 |
| 52 Week High | US$5.28 |
| 52 Week Low | US$2.37 |
| Beta | 2.43 |
| 1 Month Change | 19.23% |
| 3 Month Change | 5.68% |
| 1 Year Change | 9.41% |
| 3 Year Change | -80.51% |
| 5 Year Change | n/a |
| Change since IPO | -93.35% |
Recent News & Updates
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
May 01
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Mar 28CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Jan 08Recent updates
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
May 01CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Mar 28CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Jan 08Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
Jan 04CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13Shareholder Returns
| CVAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | 1.4% | 2.9% |
| 1Y | 9.4% | -14.7% | 11.9% |
Return vs Industry: CVAC exceeded the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: CVAC underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: CVAC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CVAC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 904 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane.
CureVac N.V. Fundamentals Summary
| CVAC fundamental statistics | |
|---|---|
| Market cap | US$837.58m |
| Earnings (TTM) | US$181.42m |
| Revenue (TTM) | US$598.64m |
4.6x
P/E Ratio1.4x
P/S RatioIs CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAC income statement (TTM) | |
|---|---|
| Revenue | €535.18m |
| Cost of Revenue | €105.63m |
| Gross Profit | €429.55m |
| Other Expenses | €267.36m |
| Earnings | €162.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 20, 2025
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 80.26% |
| Net Profit Margin | 30.30% |
| Debt/Equity Ratio | 0% |
How did CVAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 15:56 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CureVac N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Martin Auster | Credit Suisse |